Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Licenses Cystic Fibrosis Biomarkers From Johns Hopkins

NEW YORK (GenomeWeb News) — Luminex has licensed from The Johns Hopkins University genetic markers that it plans to use with its Tag-It cystic fibrosis test kits.
 
Luminex said the tests are available through its Molecular Diagnostics division, which was formerly Tm Bioscience. Luminex bought and renamed Tm Bio in March.
The non-exclusive agreement enables the company to use the IP in kits sold in the US. The license cover four mutations — 549N, 551D, 553X, and 559T — tested in the kit and two mutations, 553X and 551D, that appear in the screening panel of 23 cystic fibrosis mutations recommended by the American College of Medical Genetics and the American College of Obstetrics and Gynecology.
 
Financial terms of the agreement were not released.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.